Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation,Reduced Ability to Perform Basic Activities of Daily Living,and Low Body Mass Index in Patients with Progressed Alzheimer’s Disease
Restricted accessResearch articleFirst published online March 30, 2016
Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation,Reduced Ability to Perform Basic Activities of Daily Living,and Low Body Mass Index in Patients with Progressed Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by a central cholinergic deficit. Non-neuronal cholinergic changes are, however, described as well. Here we focused on possible changes in the activity of the plasma cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), in hospitalized AD patients. We analyzed plasma AChE and BChE activities with regards to age, gender, body mass index (BMI), cognitive functions, and ability to perform activities of daily living in AD patients in comparison to healthy subjects. We observed lower AChE activity and trend toward lower BChE activity in AD patients, which both correlated with low BMI. AD patients unable to perform basic activities of daily living (feeding, bathing, dressing, and grooming) showed reduced plasma AChE activities, while worse spatial orientation was linked to lower BChE activities. Three out of four AD patients with the lowest BChE activities died within one year. In conclusion, progressed AD was accompanied by lower plasma AChE activity and trend toward lower BChE activity, which correlated with BMI and deficits in different components of the AD.
HrabovskaA, KrejciE (2014) Reassessment of the role of the central cholinergic system. J Mol Neurosci53, 352–358.
2.
Alzheimer’s Association (2014) 2014 Alzheimer’s disease facts and figures. Alzheimers Dement10, e47–e92.
3.
RíosJA, CisternasP, ArreseM, BarjaS, InestrosaNC (2014) Is Alzheimer’s disease related to metabolic syndrome? A Wnt signaling conundrum. Prog Neurobiol121, 125–146.
4.
MatthewsDC, DaviesM, MurrayJ, WilliamsS, TsuiWH, LiY, AndrewsRD, LukicA, McHughP, VallabhajosulaS, de LeonMJ, MosconiL (2014) Physical activity, Mediterranean diet and biomarkers-assessed risk of Alzheimer’s: A multi-modality brain imaging study. Adv Mol Imaging4, 43–57.
5.
BrinkmalmA, PorteliusE, ÖhrfeltA, BrinkmalmG, AndreassonU, GobomJ, BlennowK, ZetterbergH (2015) Explorative and targeted neuroproteomics in Alzheimer’s disease. Biochim Biophys Acta1854, 769–778.
6.
HartmannJ, KiewertC, DuysenEG, LockridgeO, GreigNH, KleinJ (2007) Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem100, 1421–1429.
7.
FararV, MohrF, LegrandM, Lamotte d’IncampsB, CendelinJ, LeroyJ, AbitbolM, BernardV, BaudF, FournetV, HouzeP, KleinJ, PlaudB, TumaJ, ZimmermannM, AscherP, HrabovskaA, MyslivecekJ, KrejciE (2012) Near-complete adaptation of the PRiMA knockout to the lack of central acetylcholinesterase. J Neurochem122, 1065–1080.
8.
MassouliéJ (2002) The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals11, 130–143.
9.
CarvalhoFA, MesquitaR, Martins-SilvaJ, SaldanhaC (2004) Acetylcholine and choline effects on erythrocyte nitrite and nitrate levels. J Appl Toxicol24, 419–427.
10.
IgisuH, MatsumuraH, MatsuokaM (1994) [Acetylcholinesterase in the erythrocyte membrane]. J UOEH16, 253–262.
11.
HrabovskaA, DuysenEG, SandersJD, MurrinLC, LockridgeO (2005) Delivery of human acetylcholinesterase by adeno-associated virus to the acetylcholinesterase knockout mouse. Chem Biol Interact157–158, 71–78.
12.
LiB, StribleyJA, TicuA, XieW, SchopferLM, HammondP, BrimijoinS, HinrichsSH, LockridgeO (2000) Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem75, 1320–1331.
13.
SoreqH, SeidmanS (2001) Acetylcholinesterase–new roles for an old actor. Nat Rev Neurosci2, 294–302.
14.
LockridgeO, La DuBN (1982) Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase. J Biol Chem257, 12012–12018.
15.
LockridgeO (2015) Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther148C, 34–46.
16.
MassonP, CarlettiE, NachonF (2009) Structure, activities and biomedical applications of human butyrylcholinesterase. Protein Pept Lett16, 1215–1224.
17.
NicoletY, LockridgeO, MassonP, Fontecilla-CampsJC, NachonF (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem278, 41141–41147.
18.
WhittakerM (1980) Plasma cholinesterase variants and the anaesthetist. Anaesthesia35, 174–197.
19.
RandellEW, MathewsMS, ZhangH, SerajJS, SunG (2005) Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem38, 799–805.
20.
Calderon-MargalitR, AdlerB, AbramsonJH, GofinJ, KarkJD (2006) Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem52, 845–852.
21.
ValleA, O’ConnorDT, TaylorP, ZhuG, MontgomeryGW, SlagboomPE, MartinNG, WhitfieldJB (2006) Butyrylcholinesterase: Association with the metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem52, 1014–1020.
22.
VallianouNG, EvangelopoulosAA, BountzioukaV, BonouMS, KatsagoniC, VogiatzakisED, AvgerinosPC, BarbetseasJ, PanagiotakosDB (2014) Association of butyrylcholinesterase with cardiometabolic risk factors among apparently healthy adults. J Cardiovasc Med (Hagerstown)15, 377–383.
23.
SantarpiaL, GrandoneI, ContaldoF, PasanisiF (2013) Butyrylcholinesterase as a prognostic marker: A review of the literature. J Cachexia Sarcopenia Muscle4, 31–39.
24.
García-AyllónM-S, Riba-LlenaI, Serra-BasanteC, AlomJ, BoopathyR, Sáez-ValeroJ (2010) Altered levels of acetylcholinesterase in Alzheimer plasma. PloS One5, e8701.
25.
von BernhardiR, AlarcónR, MezzanoD, FuentesP, InestrosaNC (2005) Blood cells cholinesterase activity in early stage Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord19, 204–212.
BonoGF, Simão-SilvaDP, BatistelaMS, JosviakND, DiasPFR, NascimentoGA, SouzaRLR, PiovezanMR, SouzaRKM, Furtado-AlleL (2015) Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer’s disease in a Southern Brazilian population. Neurochem Int81, 57–62.
28.
InestrosaNC, AlarcónR, ArriagadaJ, DonosoA, AlvarezJ, CamposEO (1994) Blood markers in Alzheimer disease: Subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes. J Neurol Sci122, 1–5.
29.
St ClairDM, BrockDJ, BarronL (1986) A monoclonal antibody assay technique for plasma and red cell acetylcholinesterase activity in Alzheimer’s disease. J Neurol Sci73, 169–176.
30.
YamamotoY, NakanoS, KawashimaS, NakamuraS, UrakamiK, KatoT, KameyamaM (1990) Plasma and serum G4 isoenzyme of acetylcholinesterase in patients with Alzheimer-type dementia and vascular dementia. Ann Clin Biochem27(Pt 4), 321–326.
31.
SirviöJ, KutvonenR, SoininenH, HartikainenP, RiekkinenPJ (1989) Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer’s disease. J Neural Transm75, 119–127.
32.
RaoAA, SridharGR, DasUN (2007) Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer’s disease. Med Hypotheses69, 1272–1276.
33.
AtackJR, PerryEK, PerryRH, WilsonID, BoberMJ, BlessedG, TomlinsonBE (1985) Blood acetyl- and butyrylcholinesterases in senile dementia of Alzheimer type. J Neurol Sci70, 1–12.
34.
RoenschJ, CrisbyM, NordbergA, XiaoY, ZhangL-J, GuanZ-Z (2007) Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochem Int50, 800–806.
35.
MassonP, FromentMT, FortierPL, VisicchioJE, BartelsCF, LockridgeO (1998) Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters. Biochim Biophys Acta1387, 41–52.
36.
CarolanCG, DillonGP, GaynorJM, ReidyS, RyderSA, KhanD, MarquezJF, GilmerJF (2008) Isosorbide-2-carbamate esters: Potent and selective butyrylcholinesterase inhibitors. J Med Chem51, 6400–6409.
37.
MüllerTC, RochaJBT, MorschVM, NeisRT, SchetingerMRC (2002) Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. Biochim Biophys Acta1587, 92–98.
38.
HolmesJH, KanferI, ZwarensteinH (1978) Effect of benzodiazepine derivatives on purified blood cholinesterases in vitro. Res Commun Chem Pathol Pharmacol22, 431–432.
39.
JarvieEM, CellekS, SangerGJ (2008) Potentiation by cholinesterase inhibitors of cholinergic activity in rat isolated stomach and colon. Pharmacol Res58, 297–301.
40.
BaileyDN, BriggsJR (2005) Studies of the inhibition of serum pseudocholinesterase activity in vitro by commonly used drugs. Am J Clin Pathol124, 226–228.
41.
Laine-CessacP, TurcantA, Premel-CabicA, BoyerJ, AllainP (1993) Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Commun Chem Pathol Pharmacol79, 185–193.
42.
DingovaD, LeroyJ, CheckA, GarajV, KrejciE, HrabovskaA (2014) Optimal detection of cholinesterase activity in biological samples: Modifications to the standard Ellman’s assay. Anal Biochem462, 67–75.
43.
CohenJ (1977) Statistical power analysis for the behavioral sciences (rev. ed.)Lawrence Erlbaum Associates, Inc, Hillsdale, NJ, England.
44.
CohenJ (1992) A power primer. Psychol Bull112, 155–159.
45.
SklanEH, LowenthalA, KornerM, RitovY, LandersDM, RankinenT, BouchardC, LeonAS, RiceT, RaoDC, WilmoreJH, SkinnerJS, SoreqH (2004) Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci U S A101, 5512–5517.
46.
SidellFR, KaminskisA (1975) Influence of age, sex, and oral contraceptives on human blood cholinesterase activity. Clin Chem21, 1393–1395.
47.
ArbelY, Shenhar-TsarfatyS, WaiskopfN, FinkelsteinA, HalkinA, RevivoM, BerlinerS, HerzI, ShapiraI, KerenG, SoreqH, BanaiS (2014) Decline in serum cholinesterase activities predicts 2-year major adverse cardiac events. Mol Med Camb Mass20, 38–45.
48.
Ben AssayagE, Shenhar-TsarfatyS, OfekK, SoreqL, BovaI, ShopinL, BergRMG, BerlinerS, ShapiraI, BornsteinNM, SoreqH (2010) Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med Camb Mass16, 278–286.
49.
García-PtacekS, Faxén-IrvingG, CermákováP, EriksdotterM, ReligaD (2014) Body mass index in dementia. Eur J Clin Nutr68, 1204–1209.
50.
HerholzK (2008) Acetylcholine esterase activity in mild cognitive impairment and Alzheimer’s disease. Eur J Nucl Med Mol Imaging35(Suppl 1), S25–S29.
51.
KuhlDE, KoeppeRA, SnyderSE, MinoshimaS, FreyKA, KilbournMR (2006) In vivo butyrylcholinesterase activity is not increased in Alzheimer’s disease synapses. Ann Neurol59, 13–20.
52.
DobbertinA, HrabovskaA, DembeleK, CampS, TaylorP, KrejciE, BernardV (2009) Targeting of acetylcholinesterase in neurons in vivo: A dual processing function for the proline-rich membrane anchor subunit and the attachment domain on the catalytic subunit. J Neurosci29, 4519–4530.
53.
De FerrariGV, CanalesMA, ShinI, WeinerLM, SilmanI, InestrosaNC (2001) A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry (Mosc.)40, 10447–10457.
54.
InestrosaNC, AlvarezA, PérezCA, MorenoRD, VicenteM, LinkerC, CasanuevaOI, SotoC, GarridoJ (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: Possible role of the peripheral site of the enzyme. Neuron16, 881–891.
55.
BartoliniM, BertucciC, CavriniV, AndrisanoV (2003) beta-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharmacol65, 407–416.
56.
DuysenEG, StribleyJA, FryDL, HinrichsSH, LockridgeO (2002) Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Brain Res Dev Brain Res137, 43–54.
57.
RiceSG, NowakL, DuysenEG, LockridgeO, LahiriDK, ReyesPF (2007) Neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: Implications in Alzheimer’s disease. J Alzheimers Dis11, 481–489.
58.
HrabovskaA, FararV, BernardV, DuysenEG, BrabecJ, LockridgeO, MyslivecekJ (2010) Drastic decrease in dopamine receptor levels in the striatum of acetylcholinesterase knock-out mouse. Chem Biol Interact183, 194–201.
59.
MesulamM-M, GuillozetA, ShawP, LeveyA, DuysenEG, LockridgeO (2002) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience110, 627–639.
60.
PerryRH, BlessedG, PerryEK, TomlinsonBE (1980) Histochemical observations on cholinesterase activities in the brains of elderly normal and demented (Alzheimer-type) patients. Age Ageing9, 9–16.
61.
GeulaC, MesulamM (1989) Special properties of cholinesterases in the cerebral cortex of Alzheimer’s disease. Brain Res498, 185–189.
62.
MesulamMM, Asuncion MoránM (1987) Cholinesterases within neurofibrillary tangles related to age and Alzheimer’s disease. Ann Neurol22, 223–228.
63.
ReidGA, DarveshS (2015) Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model. Neuroscience298, 424–435.
64.
DiamantS, PodolyE, FriedlerA, LigumskyH, LivnahO, SoreqH (2006) Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A103, 8628–8633.
65.
PodolyE, BruckT, DiamantS, Melamed-BookN, WeissA, HuangY, LivnahO, LangermannS, WilgusH, SoreqH (2008) Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formationin vitro. Neurodegener Dis5, 232–236.
66.
NordbergA, BallardC, BullockR, Darreh-ShoriT, SomogyiM (2013) A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord15, pii: PCC.12r01412.
67.
PerryEK, PerryRH, BlessedG, TomlinsonBE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol4, 273–277.
68.
GreigNH, LahiriDK, SambamurtiK (2002) Butyrylcholinesterase: An important new target in Alzheimer’s disease therapy. Int Psychogeriatr14(Suppl 1), 77–91.
69.
MonacelliAM, CushmanLA, KavcicV, DuffyCJ (2003) Spatial disorientation in Alzheimer’s disease: The remembrance of things passed. Neurology61, 1491–1497.
70.
JiaJ, JiaJ, ZhouW, XuM, ChuC, YanX, SunY (2004) Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia. Chin Med J (Engl)117, 1161–1164.
71.
FararV, HrabovskaA, KrejciE, MyslivecekJ (2013) Developmental adaptation of central nervous system to extremely high acetylcholine levels. PloS One8, e68265.
72.
EmmerzaalTL, KiliaanAJ, GustafsonDR (2015) 2003-2013: A decade of body mass index, Alzheimer’s disease, and dementia. J Alzheimers Dis43, 739–755.
73.
IwasakiT, YonedaM, NakajimaA, TerauchiY (2007) Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med46, 1633–1639.
74.
DantasVGL, Furtado-AlleL, SouzaRLR, Chautard-Freire-MaiaEA (2011) Obesity and variants of the GHRL (ghrelin) and BCHE (butyrylcholinesterase) genes. Genet Mol Biol34, 205–207.
75.
AlcântaraVM, OliveiraLC, RéaRR, SuplicyHL, Chautard-Freire-MaiaEA (2005) Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem Lab Med43, 285–288.
76.
BobergDR, Furtado-AlleL, SouzaRLR, Chautard-Freire-MaiaEA (2010) Molecular forms of butyrylcholinesterase and obesity. Genet Mol Biol33, 452–454.
77.
SilvaIMW, LeiteN, BobergD, ChavesTJ, EisfeldGM, EisfeldGM, BonoGF, SouzaRLR, Furtado-AlleL (2012) Effects of physical exercise on butyrylcholinesterase in obese adolescents. Genet Mol Biol35, 741–742.
78.
ChavesTJ, LeiteN, MilanoGE, MilanoGE, SouzaRLR, Chautard-Freire-MaiaEA, Furtado-AlleL (2013) -116A and K BCHE gene variants associated with obesity and hypertriglyceridemia in adolescents from Southern Brazil. Chem Biol Interact203, 341–343.
79.
BrownCD, HigginsM, DonatoKA, RohdeFC, GarrisonR, ObarzanekE, ErnstND, HoranM (2000) Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res8, 605–619.
80.
LiB, DuysenEG, LockridgeO (2008) The butyrylcholinesterase knockout mouse is obese on a high-fat diet. Chem Biol Interact175, 88–91.
81.
ManoharanI, BoopathyR, DarveshS, LockridgeO (2007) A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta378, 128–135.
82.
MarinoLV, RamosLFA, deO, ChiarelloPG (2015) Nutritional status according to the stages of Alzheimer’s disease. Aging Clin Exp Res27, 507–513.
83.
ChenL-L, LiH, LinR, ZhengJ-H, WeiY-P, LiJ, ChenP, ChenH-Y (2015) Effects of a feeding intervention in patients with Alzheimer’s disease and dysphagia. J Clin Nurs, doi: 10.1111/jocn.13013
Lopes da SilvaS, VellasB, ElemansS, LuchsingerJ, KamphuisP, YaffeK, SijbenJ, GroenendijkM, StijnenT (2014) Plasma nutrient status of patients with Alzheimer’s disease: Systematic review and meta-analysis. Alzheimers Dement10, 485–502.
86.
AllenV, MethvenL, GosneyM (2013) The influence of nutritional supplement drinks on providing adequate calorie and protein intake in older adults with dementia. J Nutr Health Aging17, 752–755.
87.
LauqueS, Arnaud-BattandierF, GilletteS, PlazeJ-M, AndrieuS, CantetC, VellasB (2004) Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer’s disease at risk of malnutrition: A prospective randomized study. J Am Geriatr Soc52, 1702–1707.
88.
Faxén-IrvingG, BasunH, CederholmT (2005) Nutritional and cognitive relationships and long-term mortality in patients with various dementia disorders. Age Ageing34, 136–141.
DavidSM, SoundararajanL, BoopathyR (2015) The allele frequency of T920C mutation in butyrylcholinesterase gene is high in an Indian population. Gene555, 409–413.
91.
MikamiLR, WieselerS, SouzaRLR, SchopferLM, NachonF, LockridgeO, Chautard-Freire-MaiaEA (2008) Five new naturally occurring mutations of the BCHE gene and frequencies of 12 butyrylcholinesterase alleles in a Brazilian population. Pharmacogenet Genomics18, 213–218.
92.
HasinY, AvidanN, BercovichD, KorczynAD, SilmanI, BeckmannJS, SussmanJL (2005) Analysis of genetic polymorphisms in acetylcholinesterase as reflected in different populations. Curr Alzheimer Res2, 207–218.
93.
ValleAM, RadićZ, RanaBK, MahboubiV, WesselJ, ShihPB, RaoF, O’ConnorDT, TaylorP (2011) Naturally occurring variations in the human cholinesterase genes: Heritability and association with cardiovascular and metabolic traits. J Pharmacol Exp Ther338, 125–133.
94.
BoeckAT, FryDL, SastreA, LockridgeO (2002) Naturally occurring mutation, Asp70his, in human butyrylcholinesterase. Ann Clin Biochem39, 154–156.
95.
DelacourH, LushchekinaS, MabbouxI, CeppaF, MassonP, SchopferLM, LockridgeO (2014) Characterization of a novel butyrylcholinesterase point mutation (p. Ala34Val), “silent” with mivacurium. Biochem Pharmacol92, 476–483.
96.
DelacourH, LushchekinaS, MabbouxI, BousquetA, CeppaF, SchopferLM, LockridgeO, MassonP (2014) Characterization of a novel BCHE “silent” allele: Point mutation (p. Val204Asp) causes loss of activity and prolonged apnea with suxamethonium. PloS One9, e101552.
ScacchiR, GambinaG, MorettoG, CorboRM (2009) Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer’s disease and relationships with response to treatment with Donepezil and Rivastigmine. Am J Med Genet B Neuropsychiatr Genet150B, 502–507.
